Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT00591838
Previous Study | Return to List | Next Study

A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Washington University School of Medicine
Information provided by (Responsible Party):
Washington University School of Medicine Identifier:
First received: December 31, 2007
Last updated: February 8, 2017
Last verified: February 2017
The purpose of this study is to use SBRT in patients with early stage lung cancer and find out what effects (good and bad) SBRT has on their cancer. This research is being done because SBRT has not been used very often in patients with early stage lung cancer or in patients with other serious health problems. In addition, this study also will gather information about patient's health and hospitalization history. This information will be used to find out if there are any factors that can help predict recovery or outcome of patients with lung cancer.

Condition Intervention Phase
Inoperable Stage I/II Non-small Cell Lung Cancer
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree

Resource links provided by NLM:

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Phase I Portion Only: Determine the maximum tolerated dose [ Time Frame: Completion of phase I enrollment ]
  • Phase I Portion Only: Rate of acute treatment related grade 3 or 4 toxicity [ Time Frame: Up to 100 days ]
    -CTCAE version 3.0 will be used to grade toxicity

  • Phase I Portion Only: Rate of late treatment related grade 3 or 4 toxicity [ Time Frame: 101 days to 2 years ]
    -CTCAE version 3.0 will be used to grade toxicity

  • Phase II Portion Only: Determine if the MTD determined in Phase I achieves acceptable local control [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Regional nodal recurrence rate [ Time Frame: 2 years ]
  • Disseminated recurrence rate [ Time Frame: 2 years ]
  • Disease-free rate [ Time Frame: 2 years ]
  • Overall survival rate [ Time Frame: 2 years ]

Estimated Enrollment: 80
Actual Study Start Date: September 21, 2006
Estimated Study Completion Date: August 31, 2019
Estimated Primary Completion Date: August 31, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I


Dose Level A 9Gy x 5

Dose Level B 10 Gy x 5

Dose Level C 11 Gy x 5

Dose Level D 12 Gy x 5)

Radiation: Stereotactic Body Radiation Therapy (SBRT)
Experimental: Phase II
Dose will be determined in Phase II portion of study
Radiation: Stereotactic Body Radiation Therapy (SBRT)

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Inclusion Criteria

  • Histologically confirmed non-small cell cancer by biopsy or cytology. Squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar carcinoma, or non-small cell carcinoma (not otherwise specified) are allowed.
  • Staging studies must identify patient as AJCC Stage I or II based on only 1 of following combinations of TNM staging:

    • T1, N0, M0
    • T2 (<=7cm), N0, M0
    • T3 (<=7cm), N0, M0
  • Primary tumor must be arising in one of the following central chest locations:

    • Within or touching the zone of the proximal bronchial tree (a volume 2cm in all directions around the proximal bronchial tree [carina, R & L main bronchi, R & L upper lobe bronchi, intermedius bronchus, R middle lobe bronchus, lingular bronchus, R & L lower lobe bronchi])
    • Adjacent to (within 5 mm) or invading the mediastinal pleura
    • Adjacent to (within 5 mm) or invading the parietal pericardium
  • To differentiate T3 lesions involving the mediastinal pleura from T4 lesions involving major vessels or organs, a chest MRI will be obtained. If any uncertainty remains, the patient will have four-dimensional CT scans (4DCT) in an effort to determine the degree of tumor motion. A freely mobile tumor during ventilation will be judged to be T3 disease.
  • Patients with hilar or mediastinal lymph nodes <=1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with >1cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer.
  • Primary tumor must be technically resectable by an experienced thoracic cancer clinician, with a reasonable possibility of obtaining a gross total resection with negative margins (potentially curative resection, PCR). However, patients must have underlying physiological medical problems prohibiting PCR (i.e., problems with general anesthesia, the operation, the post-op recovery period, or removal of adjacent functioning lung) or refuse surgery. Deeming a patient medically inoperable based on pulmonary function for surgical resection may include any of the following: baseline FEV1 <40% predicted; post-operative predicted FEV1 <30% predicted; severely reduced diffusion capacity; baseline hypoxemia and/or hypercapnia; exercise oxygen consumption <50% predicted; severe pulmonary hypertension; diabetes with severe end organ damage; severe cerebral, cardiac, or peripheral vascular disease; or severe chronic heart disease. Any one of these problems will qualify a patient for this trial.
  • Age >=18.
  • Zubrod performance status 0-2.
  • Women of childbearing potential must use effective contraception.
  • No direct evidence of regional or distant metastases after appropriate staging studies. No synchronous primary or prior malignancy in past 2 years except non-melanoma skin cancer or in situ cancer.
  • No previous lung or mediastinal radiation therapy.
  • No plans for concomitant antineoplastic therapy (including standard fractionated RT, chemo, biologic, vaccine therapy, or surgery) while on this protocol except at disease progression.
  • No active systemic, pulmonary, or pericardial infection.
  • No pregnant or lactating women.

    • History and Physical Examination, Weight, Zubrod performance status (within 4 weeks pre-study entry)
    • Evaluation by thoracic cancer clinician (within 8 weeks pre-study entry)
    • Pregnancy test, if applicable (serum or urine, within 72 hours prior to treatment start.)
    • CT (preferably with contrast unless medically contraindicated; both lungs, mediastinum, liver, adrenals)
    • PET (using FDG with visualization of primary tumor and draining lymph node basins in hilar and mediastinal regions)
    • Brain MRI or head CT with contrast
    • PFTs - include routine spirometry, lung volumes, diffusion capacity
    • Signed informed consent.

Exclusion Criteria:

There is no exclusion criteria associated with this protocol. Please see the above inclusion criteria.-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00591838

Contact: Jeffrey D. Bradley, MD (314) 362-8525

United States, Missouri
Washington University School Recruiting
St. Louis, Missouri, United States, 63110
Contact: Jeffrey D Bradley, MD    314-362-8525   
Principal Investigator: Jeffrey D Bradley, MD         
Sub-Investigator: Clifford G Robinson, M.D.         
Sub-Investigator: Robert Drzymala, Ph.D.         
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: Jeffrey D Bradley, MD Washington University School of Medicine
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Washington University School of Medicine Identifier: NCT00591838     History of Changes
Other Study ID Numbers: 06-0691 / 201012832
Study First Received: December 31, 2007
Last Updated: February 8, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Washington University School of Medicine:

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on May 22, 2017